Lifesciences Iii, L.P.Claru... Net Worth

The estimated Net Worth of Lifesciences Iii, L.P.Claru... is at least $3.56 Milion dollars as of 28 September 2018. Lifesciences Claru owns over 453,395 units of Entasis Therapeutics Inc stock worth over $3,555,257 and over the last 6 years Lifesciences sold ETTX stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Lifesciences Claru ETTX stock SEC Form 4 insiders trading

Lifesciences has made over 1 trades of the Entasis Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Lifesciences bought 453,395 units of ETTX stock worth $6,800,925 on 28 September 2018.

The largest trade Lifesciences's ever made was buying 453,395 units of Entasis Therapeutics Inc stock on 28 September 2018 worth over $6,800,925. On average, Lifesciences trades about 453,395 units every 0 days since 2018. As of 28 September 2018 Lifesciences still owns at least 1,623,405 units of Entasis Therapeutics Inc stock.

You can see the complete history of Lifesciences Claru stock trades at the bottom of the page.

Insiders trading at Entasis Therapeutics Inc

Over the last 6 years, insiders at Entasis Therapeutics Inc have traded over $348,925 worth of Entasis Therapeutics Inc stock and bought 50,891,639 units worth $170,673,776 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Inc.Innoviva Strategic Oppo... oraz Holdings A/S Novo. On average, Entasis Therapeutics Inc executives and independent directors trade stock every 60 days with the average trade being worth of $4,855,580. The most recent stock trade was executed by Inc.Innoviva Strategic Oppo... on 8 July 2022, trading 19,270,476 units of ETTX stock currently worth $42,395,047.

What does Entasis Therapeutics Inc do?

Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis' pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections).

Complete history of Lifesciences Claru stock trades at Entasis Therapeutics Inc

Entasis Therapeutics Inc executives and stock owners

Entasis Therapeutics Inc executives and other stock owners filed with the SEC include:

• Dr. Manoussos Perros,
  Pres, CEO & Director
• Dr. David Altarac,
  Chief Medical Officer
• Dr. John Patrick Mueller Ph.D.,
  Chief Devel. Officer
• Kristie Wagner,
  Interim VP & Interim Principal Financial and Accounting Officer
• Anna Diaz Triola MBA,
  Chief Commercial Officer
• Dr. Matthew Ronsheim Ph.D.,
  Chief Pharmaceutical Sciences & Manufacturing Officer
• Colleen Tucker,
  Head of HR
• Elizabeth M. Keiley,
  Gen. Counsel
• Dr. Ruben Tommasi,
  Chief Scientific Officer
• Dr. Michael J. Gutch MBA, Ph.D.,
  CFO, Chief Bus. Officer & Sec.
• Life Sciences Viii, L.P.Top...,
  
• Anna Diaz Triola,
  Chief Commercial Officer
• Inc. Innoviva,,
  10% owner
• Venture Partners Ix, L.P.So...,
  
• Lifesciences Iii, L.P.Claru...,
  
• Group Holdings (Sbs) Adviso...,
  
• Ruben Tommasi,
  Chief Scientific Officer
• Robin Isaacs,
  Chief Medical Officer
• Nicholas Galakatos,
  Director
• James N Topper,
  Director
• Bio Venture Partners Fund I...,
  
• Life Sciences Viii, L.P.Fhm...,
  
• Plcastrazeneca Ab Astrazeneca,
  
• Holdings A/S Novo,
  10% owner
• John Patrick Mueller,
  Chief Development Officer
• Heather Preston,
  Director
• Gregory Norden,
  Director
• David C Hastings,
  Director
• Heather A. Berger,
  Director
• Howard Mayer,
  Director
• David D. Meek,
  Director
• David Altarac,
  Chief Medical Officer
• Eric Wilson Kimble,
  Chief Commercial Officer
• Elizabeth M Keiley,
  General Counsel
• Kristie Ann Wagner,
  VP, Principal Fin & Acct Off
• Inc.Innoviva Strategic Oppo...,
  
• Manoussos Perros,
  President and CEO
• Michael Gutch,
  See Remarks
• Matthew Ronsheim,
  Chief of Pharma Sciences & MFG